Property:Outcome name
No edit summary |
No edit summary |
||
| (8 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
The allowed values for this property are: | The allowed values for this property are: | ||
* [[Allows value::Additional medication]] | |||
* [[Allows value::Anorexia/Cachexia]] | * [[Allows value::Anorexia/Cachexia]] | ||
* [[Allows value::Antibodies]] | * [[Allows value::Antibodies]] | ||
* [[Allows value::Anxiety]] | * [[Allows value::Anxiety]] | ||
* [[Allows value::Appetite]] | * [[Allows value::Appetite]] | ||
* [[Allows value::Arterial inflow]] | |||
* [[Allows value::BMD (Bone Mineral Density)]] | |||
* [[Allows value::Body composition]] | * [[Allows value::Body composition]] | ||
* [[Allows value::Carnitine level]] | * [[Allows value::Carnitine level]] | ||
* [[Allows value::Carotenoid concentration]] | * [[Allows value::Carotenoid concentration]] | ||
| Line 19: | Line 21: | ||
* [[Allows value::Diarrhoe]] | * [[Allows value::Diarrhoe]] | ||
* [[Allows value::Distress]] | * [[Allows value::Distress]] | ||
* [[Allows value::Dysgeusia]] | * [[Allows value::Dysgeusia]] | ||
* [[Allows value::Ejection fraction]] | * [[Allows value::Ejection fraction]] | ||
* [[Allows value::Erectile dysfunction]] | * [[Allows value::Erectile dysfunction]] | ||
* [[Allows value::Erythema]] | |||
* [[Allows value::Esophagitis]] | * [[Allows value::Esophagitis]] | ||
* [[Allows value::Fatigue]] | * [[Allows value::Fatigue]] | ||
* [[Allows value::Fever]] | |||
* [[Allows value::Fibrosis]] | * [[Allows value::Fibrosis]] | ||
* [[Allows value::Folic acid level]] | * [[Allows value::Folic acid level]] | ||
| Line 34: | Line 35: | ||
* [[Allows value::Hand-foot syndrome]] | * [[Allows value::Hand-foot syndrome]] | ||
* [[Allows value::Hand grip strength]] | * [[Allows value::Hand grip strength]] | ||
* [[Allows value::Hormone level]] | * [[Allows value::Hormone level]] | ||
* [[Allows value::Incidence of acute GVHD (Graft-Versus-Host Disease)]] | * [[Allows value::Incidence of acute GVHD (Graft-Versus-Host Disease)]] | ||
* [[Allows value::Infection]] | |||
* [[Allows value::Interaction with cancer treatment]] | |||
* [[Allows value::Ileus (intestinal obstruction)]] | * [[Allows value::Ileus (intestinal obstruction)]] | ||
* [[Allows value::Laboratory parameters]] | |||
* [[Allows value::Length of hospital stay]] | * [[Allows value::Length of hospital stay]] | ||
* [[Allows value::Lymphedema]] | * [[Allows value::Lymphedema]] | ||
* [[Allows value::Menopausal symptoms]] | * [[Allows value::Menopausal symptoms]] | ||
* [[Allows value:: | * [[Allows value::Mental status/ function]] | ||
* [[Allows value::Mood/Affect]] | * [[Allows value::Mood/Affect]] | ||
* [[Allows value::Mortality rate]] | * [[Allows value::Mortality rate]] | ||
* [[Allows value::Mucositis]] | * [[Allows value::Mucositis]] | ||
* [[Allows value::Musculoskeletal symptoms]] | * [[Allows value::Musculoskeletal symptoms]] | ||
* [[Allows value::Nausea]] | * [[Allows value::Nausea]] | ||
* [[Allows value::Nausea and Vomiting]] | * [[Allows value::Nausea and Vomiting]] | ||
* [[Allows value:: | * [[Allows value::Nerve conduction velocity]] | ||
* [[Allows value::Neurotoxicity]] | |||
* [[Allows value::Neutropenia]] | * [[Allows value::Neutropenia]] | ||
* [[Allows value::Non-haematological indices]] | * [[Allows value::Non-haematological indices]] | ||
* [[Allows value::Nutrition status]] | * [[Allows value::Nutrition status]] | ||
* [[Allows value::Objective signs and subjective symptoms]] | * [[Allows value::Objective signs and subjective symptoms]] | ||
* [[Allows value::Oral ulcus]] | |||
* [[Allows value::OS (Overall Survival)]] | * [[Allows value::OS (Overall Survival)]] | ||
* [[Allows value::Ototoxicity]] | * [[Allows value::Ototoxicity]] | ||
* [[Allows value::Pain]] | * [[Allows value::Pain]] | ||
* [[Allows value::PD (Pharmacodynamics)]] | |||
* [[Allows value::Performance Status]] | * [[Allows value::Performance Status]] | ||
* [[Allows value::Peripheral neuropathy]] | |||
* [[Allows value::PFS (Progression-Free Survival)]] | * [[Allows value::PFS (Progression-Free Survival)]] | ||
* [[Allows value::Pharyngitis]] | * [[Allows value::Pharyngitis]] | ||
* [[Allows value:: | * [[Allows value::Physical functioning]] | ||
* [[Allows value::PK (Pharmacokinetics)]] | |||
* [[Allows value::Postoperative morbidity/ complications]] | |||
* [[Allows value::PSA level (Prostate-Specific Antigen)]] | * [[Allows value::PSA level (Prostate-Specific Antigen)]] | ||
* [[Allows value::Quality of life]] | * [[Allows value::Quality of life]] | ||
* [[Allows value::Recurrence rate]] | * [[Allows value::Recurrence rate]] | ||
* [[Allows value:: | * [[Allows value::REE (Resting Energy Expenditure)]] | ||
* [[Allows value::Relaxation]] | * [[Allows value::Relaxation]] | ||
* [[Allows value::RFS (Recurrence-Free Survival)]] | * [[Allows value::RFS (Recurrence-Free Survival)]] | ||
* [[Allows value::Salivary gland function]] | * [[Allows value::Salivary gland function]] | ||
* [[Allows value::Seroconversion]] | * [[Allows value::Seroconversion]] | ||
* [[Allows value::Selenium level]] | * [[Allows value::Selenium level]] | ||
* [[Allows value::Sleep]] | * [[Allows value::Sleep]] | ||
* [[Allows value::Stomatitis]] | |||
* [[Allows value::Stress]] | * [[Allows value::Stress]] | ||
* [[Allows value::Symptom load]] | |||
* [[Allows value::Taste alteration]] | * [[Allows value::Taste alteration]] | ||
* [[Allows value::Tea polyphenol uptake]] | * [[Allows value::Tea polyphenol uptake]] | ||
* [[Allows value::Thromboembolic event rates]] | * [[Allows value::Thromboembolic event rates]] | ||
* [[Allows value::Toxicity]] | * [[Allows value::Toxicity]] | ||
* [[Allows value::Treatment interruption]] | |||
* [[Allows value::Tumor progression]] | * [[Allows value::Tumor progression]] | ||
* [[Allows value::Tumor response]] | * [[Allows value::Tumor response]] | ||
Latest revision as of 14:22, 28 November 2024
This is a property of type Text.
The allowed values for this property are:
- Additional medication
- Anorexia/Cachexia
- Antibodies
- Anxiety
- Appetite
- Arterial inflow
- BMD (Bone Mineral Density)
- Body composition
- Carnitine level
- Carotenoid concentration
- Cerebral oedema
- CINV (Chemotherapy-Induced Nausea and Vomiting)
- Cognitive functioning
- Cognitive impairment
- Depression
- Dermatitis
- DFS (Disease-Free Survival)
- Diarrhoe
- Distress
- Dysgeusia
- Ejection fraction
- Erectile dysfunction
- Erythema
- Esophagitis
- Fatigue
- Fever
- Fibrosis
- Folic acid level
- Functionality
- Haematological indices
- Haematological toxicity
- Hand-foot syndrome
- Hand grip strength
- Hormone level
- Incidence of acute GVHD (Graft-Versus-Host Disease)
- Infection
- Interaction with cancer treatment
- Ileus (intestinal obstruction)
- Laboratory parameters
- Length of hospital stay
- Lymphedema
- Menopausal symptoms
- Mental status/ function
- Mood/Affect
- Mortality rate
- Mucositis
- Musculoskeletal symptoms
- Nausea
- Nausea and Vomiting
- Nerve conduction velocity
- Neurotoxicity
- Neutropenia
- Non-haematological indices
- Nutrition status
- Objective signs and subjective symptoms
- Oral ulcus
- OS (Overall Survival)
- Ototoxicity
- Pain
- PD (Pharmacodynamics)
- Performance Status
- Peripheral neuropathy
- PFS (Progression-Free Survival)
- Pharyngitis
- Physical functioning
- PK (Pharmacokinetics)
- Postoperative morbidity/ complications
- PSA level (Prostate-Specific Antigen)
- Quality of life
- Recurrence rate
- REE (Resting Energy Expenditure)
- Relaxation
- RFS (Recurrence-Free Survival)
- Salivary gland function
- Seroconversion
- Selenium level
- Sleep
- Stomatitis
- Stress
- Symptom load
- Taste alteration
- Tea polyphenol uptake
- Thromboembolic event rates
- Toxicity
- Treatment interruption
- Tumor progression
- Tumor response
- Vaginal atrophy
- Vitamin A level
- Vitamin B6 level
- Vitamin B12 level
- Vitamin B17 level
- Vitamin C level
- Vitamin D level
- Vitamin E level
- Vomiting
- Weight
- Well-being
- Wound healing
- Wound odour
- Xerostomia
- Zinc level
- Unspecified effects
- NI
- ?
A
Afonseca et al. (2013): Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: A pilot randomized clinical trial +
Toxicity +
Afonseca et al. (2013): Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: A pilot randomized clinical trial +
Peripheral neuropathy +
Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial +
RFS (Recurrence-Free Survival) +
Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial +
OS (Overall Survival) +
Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial +
Vitamin D level +
Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy +
Nausea +
Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy +
Vomiting +
OS (Overall Survival) +
PFS (Progression-Free Survival) +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
Mucositis +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
Xerostomia +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
Quality of life +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
Pain +
Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results +
Peripheral neuropathy +
Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results +
Functionality +
Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation +
Peripheral neuropathy +
Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation +
Functionality +
Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer +
CINV (Chemotherapy-Induced Nausea and Vomiting) +
Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer +
CINV (Chemotherapy-Induced Nausea and Vomiting) +
Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer +
CINV (Chemotherapy-Induced Nausea and Vomiting) +
Showing 1 related entity.
{ "type": "PROPERTY_CONSTRAINT_SCHEMA", "constraints": { "type_constraint": "_txt", "allowed_values": [ "Anorexia/Cachexia", "Anxiety", "Appetite", "Cerebral oedema", "Cognitive functioning", "Cognitive impairment", "Depression", "Dermatitis", "Distress", "Dysgeusia", "Ejection fraction", "Erectile dysfunction", "Fatigue", "Haematological toxicity", "Hand-foot syndrome", "Ileus (intestinal obstruction)", "Lymphedema", "Menopausal symptoms", "Mood/Affect", "Mucositis", "Nausea", "Nausea and Vomiting", "Neutropenia", "Ototoxicity", "Pain", "Quality of life", "Recurrence rate", "Relaxation", "Stress", "Toxicity", "Vaginal atrophy", "Vomiting", "Weight", "Well-being", "Wound healing", "Xerostomia", "?", "NI", "Esophagitis", "Seroconversion", "Antibodies", "Carnitine level", "Folic acid level", "Haematological indices", "Incidence of acute GVHD (Graft-Versus-Host Disease)", "Length of hospital stay", "Mortality rate", "Non-haematological indices", "Performance Status", "Selenium level", "Tumor response", "Vitamin A level", "Vitamin B6 level", "Vitamin B12 level", "Vitamin B17 level", "Vitamin C level", "Vitamin D level", "Vitamin E level", "Zinc level", "OS (Overall Survival)", "Body composition", "Diarrhoe", "Nutrition status", "PSA level (Prostate-Specific Antigen)", "Taste alteration", "Tumor progression", "DFS (Disease-Free Survival)", "PFS (Progression-Free Survival)", "RFS (Recurrence-Free Survival)", "Carotenoid concentration", "Pharyngitis", "CINV (Chemotherapy-Induced Nausea and Vomiting)", "Fibrosis", "Functionality", "Hand grip strength", "Hormone level", "Musculoskeletal symptoms", "Objective signs and subjective symptoms", "Salivary gland function", "Thromboembolic event rates", "Wound odour", "BMD (Bone Mineral Density)", "PD (Pharmacodynamics)", "Sleep", "Tea polyphenol uptake", "Unspecified effects", "Peripheral neuropathy", "PK (Pharmacokinetics)", "Arterial inflow", "Erythema", "Laboratory parameters", "Mental status/ function", "Neurotoxicity", "Oral ulcus", "Physical functioning", "Additional medication", "Interaction with cancer treatment", "REE (Resting Energy Expenditure)", "Treatment interruption", "Fever", "Infection", "Nerve conduction velocity", "Postoperative morbidity/ complications", "Stomatitis", "Symptom load" ] } }